Response to COVID-19 mRNA Vaccination in Patients with Multiple Sclerosis on anti-CD20 Disease Modifying Therapies

被引：0
|
作者：
Wolf, Andrew [1 ]
Pratt, Robert W. [1 ]
Crooks, Kristy [2 ,3 ]
Borko, Tyler [1 ]
Gonzalez, Jose Parra [1 ]
Vollmer, Timothy [1 ]
Frazer-Abel, Ashley [4 ,5 ]
机构：
[1] Univ Colorado, Dept Neurol, Aurora, CO USA
[2] Univ Colorado, Sch Med, Colorado Mol Correlates Lab CMOCO, Aurora, CO USA
[3] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA
[4] Univ Colorado, Sch Med, Exsera BioLabs, Aurora, CO USA
[5] Univ Colorado, Sch Med, Dept Med, Div Rheumatol, Aurora, CO USA
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
340
引用
收藏
页码：S179 / S180
页数：2
相关论文
共 50 条
  • [31] Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies
    Etemadifar, Masoud
    Sami, Ramin
    Salari, Mehri
    Sedaghat, Nahad
    Sigari, Amirhossein Akhavan
    Aghababaei, Ali
    Najafi, Mohammadreza
    Tehrani, Donya Sheibani
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2021, 26 (01):
  • [32] Effects of Multiple Sclerosis Disease-Modifying Therapies on Immunological Responses to COVID-19 Vaccination in Hispanic Puerto Rican Patients
    Vega-Corteguera, R.
    Carmona-Burgos, D.
    Martinez-Maldonado, V.
    Gilman, C.
    Diaz-de la Matta, P.
    Vicente-Loperena, I.
    Chinea-Martinez, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 79 - 80
  • [33] Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland
    Podlecka-Pietowska, Aleksandra
    Sierdzinski, Janusz
    Nojszewska, Monika
    Stawicki, Jakub
    Bartosik-Psujek, Halina
    Lech, Beata
    Popiel, Malgorzata
    Perenc, Adam
    Kulakowska, Alina
    Czarnowska, Agata
    Kulikowska, Joanna
    Kapica-Topczewska, Katarzyna
    Jamroz-Wisniewska, Anna
    Rejdak, Konrad
    Zaborski, Jacek
    Kubicka-Baczyk, Katarzyna
    Niedziela, Natalia
    Wierzbicki, Krzysztof
    Adamczyk-Sowa, Monika
    Zwiernik, Jacek
    Zwiernik, Beata
    Milewska-Jedrzejczak, Marta
    Glabinski, Andrzej
    Jasinska, Elzbieta
    Puz, Przemyslaw
    Krzystanek, Ewa
    Steposz, Arkadiusz
    Karuga, Aleksandra
    Bal, Anetta Lasek-
    Siuda, Joanna
    Ksciuk, Barbara
    Walawska-Hrycek, Anna
    Patalong-Ogiewa, Maja
    Kaczmarczyk, Aleksandra
    Siutka, Katarzyna
    Brola, Waldemar
    Zakrzewska-Pniewska, Beata
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2024, 58 (01) : 112 - 119
  • [34] Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
    Simpson-Yap, Steve
    De Brouwer, Edward
    Kalincik, Tomas
    Rijke, Nick
    Hillert, Jan A.
    Walton, Clare
    Edan, Gilles
    Moreau, Yves
    Spelman, Tim
    Geys, Lotte
    Parciak, Tina
    Gautrais, Clement
    Lazovski, Nikola
    Pirmani, Ashkan
    Ardeshirdavanai, Amin
    Forsberg, Lars
    Glaser, Anna
    McBurney, Robert
    Schmidt, Hollie
    Bergmann, Arnfin B.
    Braune, Stefan
    Stahmann, Alexander
    Middleton, Rodden
    Salter, Amber
    Fox, Robert J.
    van der Walt, Anneke
    Butzkueven, Helmut
    Alroughani, Raed
    Ozakbas, Serkan
    Rojas, Juan, I
    van der Mei, Ingrid
    Nag, Nupur
    Ivanov, Rumen
    do Olival, Guilherme Sciascia
    Dias, Alice Estavo
    Magyari, Melinda
    Brum, Doralina
    Mendes, Maria Fernanda
    Alonso, Ricardo N.
    Nicholas, Richard S.
    Bauer, Johana
    Chertcoff, Anibal Sebastian
    Zabalza, Anna
    Arrambide, Georgina
    Fidao, Alexander
    Comi, Giancarlo
    Peeters, Liesbet
    NEUROLOGY, 2021, 97 (19) : E1870 - E1885
  • [35] Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications-A pilot study
    Moser, Tobias
    Otto, Ferdinand
    O'Sullivan, Ciara
    Hitzl, Wolfgang
    Pilz, Georg
    Harrer, Andrea
    Trinka, Eugen
    Wipfler, Peter
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
  • [36] Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
    Spierer, Ronen
    Lavi, Idit
    Bloch, Sivan
    Mazar, Marianna
    Golan, Daniel
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 4632 - 4639
  • [37] Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
    Ronen Spierer
    Idit Lavi
    Sivan Bloch
    Marianna Mazar
    Daniel Golan
    Journal of Neurology, 2023, 270 : 4632 - 4639
  • [38] Risk of COVID-19 after vaccination among people with multiple sclerosis who are treated with disease modifying therapies
    Golan, D.
    Lavi, I.
    Bloch, S.
    Saliba, W.
    Awni, Y.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 874 - 874
  • [39] A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies
    Pascual Torres
    Agustín Sancho-Saldaña
    Anna Gil Sánchez
    Silvia Peralta
    Maria José Solana
    Sofian Bakkioui
    Cristina González-Mingot
    Laura Quibus
    Emilio Ruiz-Fernández
    Eduardo San Pedro-Murillo
    Luis Brieva
    Journal of Neurology, 2023, 270 : 2380 - 2391
  • [40] A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies
    Torres, Pascual
    Sancho-Saldana, Agustin
    Sanchez, Anna Gil
    Peralta, Silvia
    Solana, Maria Jose
    Bakkioui, Sofian
    Gonzalez-Mingot, Cristina
    Quibus, Laura
    Ruiz-Fernandez, Emilio
    San Pedro-Murillo, Eduardo
    Brieva, Luis
    JOURNAL OF NEUROLOGY, 2023, 270 (05) : 2380 - 2391
12345